Barclays
PALI icon

Barclays’s Palisade Bio PALI Stock Holding History

Barclays’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.8K Buy
36,253
+34,023
+1,526% +$67K ﹤0.01% 4165
2026
Q1 		$3.9K Sell
2,230
-12,550
-85% -$22.8K ﹤0.01% 4796
2025
Q4 		$34.7K Buy
+14,780
New +$28.4K ﹤0.01% 4794
2025
Q2 		– Sell
-6
Closed -$4 – 5460
2025
Q1 		$4 Buy
+6
New +$7 ﹤0.01% 5199
2015
Q2 		– Hold
0
– -$1K – 7145
2015
Q1 		– Hold
0
– – – 6984
2014
Q4 		– Hold
0
– – – 6825
2014
Q3 		– Hold
0
– – – 7410
2014
Q2 		– Hold
0
– – – 7069

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Barclays's PALI Position: Q2 2026 in Review

Barclays increased its Palisade Bio (PALI) stake by 1,526% in Q2 2026, buying an estimated $67K and bringing the position to 36,253 shares worth $75.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Barclays first reported a position in PALI in Q1 2025 and has held it in 4 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Barclays held 36,253 shares of Palisade Bio worth $75.8K as of Q2 2026.
  • Barclays bought 34,023 Palisade Bio shares in Q2 2026, an estimated $67K.
  • Palisade Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4165 holding.
  • Barclays first reported a position in Palisade Bio in Q1 2025 and has held it in 4 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.